Last reviewed · How we verify
bupivacaine 0.25% And verapamil
bupivacaine 0.25% And verapamil is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved.
Bupivacaine 0.25% and verapamil, marketed by Ain Shams University, is a combination drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the potential for continued revenue generation until the patent expiry. The primary risk is the loss of exclusivity post-2028, which could lead to increased competition and market share erosion.
At a glance
| Generic name | bupivacaine 0.25% And verapamil |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Verapamil as an Adjuvant to Local Anaethetics in Supraclav Block for Hand Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupivacaine 0.25% And verapamil CI brief — competitive landscape report
- bupivacaine 0.25% And verapamil updates RSS · CI watch RSS
- Ain Shams University portfolio CI